

Medigen Biotechnology Corp. (3176 MEDIGEN)					
SEQ_NO	1	Date of announcement	2023/08/08	Time of announcement	17:43:46
Subject	The Company's 2023 Q2 consolidated financial statements have been approved by the Board of Directors				
Date of events	2023/08/08	To which item it meets	paragraph 31		
Statement	<ol style="list-style-type: none"> 1. Date of the board of directors submitted or approved: 2023/08/08 2. Date of the audit committee approved: 2023/08/08 3. Start and end dates of financial reports or unaudited financial information of the reporting period (XXXX/XX/XX~XXXX/XX/XX): 2023/01/01~2023/06/30 4. Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 369,814 5. Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD): 186,106 6. Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD): (593,159) 7. Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD): (584,372) 8. Profit (loss) accumulated from 1/1 to end of the period (thousand NTD): (603,112) 9. Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD): (192,027) 10. Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD): (1.38) 11. Total assets end of the period (thousand NTD): 9,259,865 12. Total liabilities end of the period (thousand NTD): 3,458,443 13. Equity attributable to owners of parent end of the period (thousand NTD): 1,901,236 14. Any other matters that need to be specified: None 				